rs9514828
This is a regulatory region variant variant in the TNFSF13B gene.
▶Research that mentions this SNP (1)
▶Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non‐Hodgkin lymphomaFunctionalN=30Stephen M. Ansell et al.(2009)· American Journal of Hematology
This study measured serum B-lymphocyte stimulator (BLyS) levels before and after rituximab treatment in 30 patients with previously untreated follicular Grade 1 non-Hodgkin lymphoma. Serum BLyS levels increased significantly after rituximab therapy (mean 4.47 ng/ml pre-treatment to 10.75 ng/ml post-treatment, P=0.0001), independent of four polymorphisms in the BLyS gene (TNFSF13B: rs12428930, rs12583006, rs1224141, rs9514828). While the increase in BLyS did not correlate with time to progression or overall survival, patients with higher post-rituximab BLyS levels were more likely to have complete response.
About TNFSF13B
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011]
View all TNFSF13B variants →Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…